The financing volume of European Biotech seed stage companies has significantly increased in recent years. Since 2017, the funding volume has increased by roughly 200% to EUR 296m in 2021 to date. In June this year, the accumulated volume in 2021 had already exceeded the total volume of 2020.
In addition, the average seed financing volume in 2021 to date is EUR 4.7m compared to EUR 2.9m in 2020 which indicates a tendency to larger seed funding rounds in the European Biotech space. The largest seed round since 2017 has been raised by Mestag Therapeutics in May 2021 in the amount of EUR 37m.
About FCF Life Sciences
FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.
Learn more about FCF Life Sciences, click here.
We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.
To hear from us on the latest insights, please sign up here: